# Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

> **NCT03452592** · PHASE2 · TERMINATED · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 220 (actual)

## Conditions studied

- Advanced NSCLC Patients With T790M

## Interventions

- **DRUG:** Alflutinib

## Key facts

- **NCT ID:** NCT03452592
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-30
- **Primary completion:** 2021-04-21
- **Final completion:** 2024-03-14
- **Target enrollment:** 220 (ACTUAL)
- **Why stopped:** Indications have been approved for marketing
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03452592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03452592, "Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03452592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*